Cheng, Y., Lu, L., Zhuang, W., Zhu, D., Zhao, Y., Li, N., Guo, Y., Hui, Z., Li, Y., Wang, Z., Zhang, P., Wang, Y. (2025). First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.8511